Mineralocorticoid Receptor Antagonists
-
Subject Areas on Research
-
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study.
-
Acute coronary syndromes: Treatment for low-risk patients with STEMI--challenges remain.
-
Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death.
-
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
-
Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction.
-
Aldosterone antagonists--last man standing?
-
Aldosterone: Behind the Scenes of Depression and Heart Failure?
-
Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
-
Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF.
-
Association of achieved blood pressure after treatment for primary aldosteronism with long-term kidney function.
-
Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.
-
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT.
-
Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.
-
Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.
-
Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.
-
Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.
-
Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
-
Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
-
Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure.
-
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
-
Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
-
Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data.
-
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
-
Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure.
-
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
-
Diuretics and ultrafiltration in acute decompensated heart failure.
-
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
-
Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.
-
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
-
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
-
Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
-
Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study.
-
Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction.
-
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
-
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
-
Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.
-
Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction.
-
Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team.
-
Heart failure medications prescribed at discharge for patients with left ventricular assist devices.
-
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.
-
Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
-
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.
-
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.
-
Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display.
-
Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
-
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
-
Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly.
-
Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure.
-
Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications.
-
Left ventricular dysfunction: causes, natural history, and hopes for reversal.
-
Lessons from the TOPCAT trial.
-
Longitudinal Strain in Heart Failure With Preserved Ejection Fraction: Is There a Role for Prognostication?
-
Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply.
-
Management of acute decompensated heart failure.
-
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
-
Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease.
-
Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
-
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
-
Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
-
Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction.
-
Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF.
-
Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope.
-
Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry.
-
Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
-
Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
-
New York Heart Association functional class predicts exercise parameters in the current era.
-
Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.
-
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
-
Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
-
Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
-
Post-Myocardial Infarction Heart Failure.
-
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
-
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
-
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
-
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
-
Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.
-
Relationships between emerging measures of heart failure processes of care and clinical outcomes.
-
Role of AT₁ receptor-mediated salt retention in angiotensin II-dependent hypertension.
-
Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials).
-
Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed.
-
Spironolactone and Cardiac Arrhythmias in Hemodialysis Patients: Helpful or Harmful?
-
Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.
-
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.
-
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
-
Strategies to attenuate pathological remodeling in heart failure.
-
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
-
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
-
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction.
-
The ABCs of managing systolic heart failure: Past, present, and future.
-
The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
-
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.
-
The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity.
-
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
-
The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic.
-
Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure.
-
Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
-
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
-
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications.
-
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.
-
Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
-
Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG).
-
Use of aldosterone antagonists in heart failure.
-
Usefulness of spironolactone in a specialized heart failure clinic.
-
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
-
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
-
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
-
Keywords of People
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Mentz, Robert John,
Associate Professor of Medicine,
Medicine, Cardiology
-
O'Connor, Christopher Michael,
Adjunct Professor in the Department of Medicine,
Medicine, Clinical Pharmacology